{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:44:47Z","timestamp":1789454687459,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022219","name":"South Carolina Rural Infrastructure Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jtct.2024.07.001","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T21:24:38Z","timestamp":1720214678000},"page":"923.e1-923.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-7588","authenticated-orcid":false,"given":"Dawoon","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janel R.","family":"Long-Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-2767","authenticated-orcid":false,"given":"Wendy W.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8348-4295","authenticated-orcid":false,"given":"Jogarao V.S.","family":"Gobburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jtct.2024.07.001_bib0001","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.bbmt.2019.03.008","article-title":"Low exposure busulfan conditioning to achieve sufficient multilineage chimerism in patients with severe combined immunodeficiency","volume":"25","author":"Dvorak","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.001_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40124-014-0071-7","article-title":"hematopoietic stem cell transplantation for severe combined immunodeficiency","volume":"3","author":"Wahlstrom","year":"2015","journal-title":"Curr Pediatr Rep"},{"key":"10.1016\/j.jtct.2024.07.001_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108778","article-title":"Expectations and experience: parent and patient perspectives regarding treatment for Severe Combined Immunodeficiency (SCID)","volume":"229","author":"Smith","year":"2021","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.jtct.2024.07.001_bib0004","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaci.2023.02.015","article-title":"Gene therapy for SCID, now up to 3!","volume":"151","author":"Fischer","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jtct.2024.07.001_bib0005","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood.V99.3.872","article-title":"Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival","volume":"99","author":"Myers","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2024.07.001_bib0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.001_bib0007","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2020.09.020","article-title":"Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2024.07.001_bib0008","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.07.001_bib0009","series-title":"The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies","author":"Carreras","year":"2019"},{"issue":"7","key":"10.1016\/j.jtct.2024.07.001_bib0010","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","article-title":"Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \u201cwhen and for whom\u201d in 2021?","volume":"106","author":"Gagelmann","year":"2021","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.jtct.2024.07.001_bib0011","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","article-title":"Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice","volume":"133","author":"Kwon","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2024.07.001_bib0012","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-137762","article-title":"First report of non-genotoxic conditioning with JSP191 (anti-CD117) and hematopoietic stem cell transplantation in a newly diagnosed patient with severe combined immune deficiency","volume":"136","author":"Agarwal","year":"2020","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2024.07.001_bib0013","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1200\/JCO.2021.39.15_suppl.7035","article-title":"Early results of phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with non-myeloablative conditioning in older adults with MRD-positive MDS\/AML undergoing allogeneic hematopoietic cell transplantation","volume":"39","author":"Muffly","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2024.07.001_bib0014","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/bcp.13996","article-title":"Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology","volume":"85","author":"Bajaj","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.jtct.2024.07.001_bib0015","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of Monoclonal Antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"10.1016\/j.jtct.2024.07.001_bib0016","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcph.1545","article-title":"Concept of pharmacologic target-mediated drug disposition (TMDD) in large-molecule and small-molecule compounds","volume":"60","author":"An","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jtct.2024.07.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1964935","article-title":"Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings","volume":"13","author":"Germovsek","year":"2021","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.jtct.2024.07.001_bib0018","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.4161\/mabs.29095","article-title":"A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design","volume":"6","author":"Davda","year":"2014","journal-title":"MAbs"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724004949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724004949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:02:06Z","timestamp":1762639326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724004949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2666636724004949"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.07.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}